GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

Tekijä Roth, Jonathan D, Erickson, Mary R, Chen, Steve, Parkes, David G
Julkaistu 2012

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

Tekijä Papazyan, Romeo, Liu, Xueqing, Liu, Jingwen, Dong, Bin, Plummer, Emily M., Lewis, Ronald D., Roth, Jonathan D., Young, Mark A.
Julkaisussa J Lipid Res (2018)

Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies

Tekijä Roth, Jonathan D., Roland, Barbara L., Cole, Rebecca L., Trevaskis, James L., Weyer, Christian, Koda, Joy E., Anderson, Christen M., Parkes, David G., Baron, Alain D.
Julkaistu 2008

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis

Tekijä Roth, Jonathan D, Feigh, Michael, Veidal, Sanne S, Fensholdt, Louise KD, Rigbolt, Kristoffer T, Hansen, Henrik H, Chen, Li C, Petitjean, Mathieu, Friley, Weslyn, Vrang, Niels, Jelsing, Jacob, Young, Mark
Julkaisussa World J Gastroenterol (2018)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

Tekijä Roth, Jonathan D., Veidal, Sanne S., Fensholdt, Louise K. D., Rigbolt, Kristoffer T. G., Papazyan, Romeo, Nielsen, Jens Christian, Feigh, Michael, Vrang, Niels, Young, Mark, Jelsing, Jacob, Adorini, Luciano, Hansen, Henrik H.
Julkaisussa Sci Rep (2019)